Page last updated: 2024-11-05

pyromellitic dianhydride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6966
CHEMBL ID3182140
SCHEMBL ID15763
MeSH IDM0058718

Synonyms (69)

Synonym
1,4,5-benzenetetracarboxylic 1,2:4,5-dianhydride
1h,2-c:4,5-c']difuran-1,3,5,7-tetrone
nsc-4798
pyromellitic anhydride
nsc4798
pyromellitic acid dianhydride
pyromellitic dianhydride
pyromellitic acid anhydride
89-32-7
1,2,4,5-benzenetetracarboxylic anhydride ,
1,2,4,5-benzenetetracarboxylic dianhydride
1h,3h-benzo[1,2-c:4,5-c']difuran-1,3,5,7-tetrone
inchi=1/c10h2o6/c11-7-3-1-4-6(10(14)16-8(4)12)2-5(3)9(13)15-7/h1-2
nsc 4798
1h,3h-benzo(1,2-c:4,5-c')difuran-1,3,5,7-tetrone
1,2,4,5 benzenetetracarboxylic 1,2:4,5 dianhydride
pyromellitic 1,2:4,5-dianhydride
hsdb 6950
benzene-1,2:4,5-tetracarboxylic dianhydride
1,2,4,5-benzenetetracarboxylic 1,2:4,5-dianhydride
einecs 201-898-9
OPREA1_783432
benzo[1,2-c
furo[3,4-f]isobenzofuran-1,3,5,7-tetrone
4,5-c']difuran-1,3,5,7-tetraone
pyromellitic dianhydride, 97%
NCGC00164170-01
AC-11735
B0040
benzene-1,2,4,5-tetracarboxylic dianhydride
furo[3,4-f][2]benzofuran-1,3,5,7-tetrone
benzo[1,2-c:4,5-c']difuran-1,3,5,7-tetraone
AKOS000120068
NCGC00164170-02
2z22t30qzq ,
unii-2z22t30qzq
pmda
tox21_303118
NCGC00256972-01
dtxcid906536
dtxsid1026536 ,
cas-89-32-7
tox21_201714
NCGC00259263-01
5,11-dioxatricyclo[7.3.0.0^{3,7}]dodeca-1,3(7),8-triene-4,6,10,12-tetrone
pyromellitic dianhydride [hsdb]
1,2,4,5-benzenetetracarboxylic acid 1,2:4,5-dianhydride
1,2,4,5-benzenetetracarboxylic acid dianhydride
STL477627
SCHEMBL15763
pyromellitic dianhydride (pmda)
benzene-1,2,4,5-tetracarboxylic acid dianhydride
W-100378
STR04559
CHEMBL3182140
P2103
F0001-2194
mfcd00005005
Z57127502
pyromellitic dianhydride (purified by sublimation)
1h,3h-furo[3,4-f][2]benzofuran-1,3,5,7-tetrone
Q1407366
EN300-18019
5,11-dioxatricyclo[7.3.0.0,3,7]dodeca-1,3(7),8-triene-4,6,10,12-tetrone
1-pmda
D92186
A916668
1.2.4.5-benzenetetracarboxylic anhydride
1h,3h-benzo(1,2-c;4,5-c')difuran-1,3,5,7-tetrone

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" NS have the ability to enhance the stability, solubility and bioavailability of various actives."( Carboxylate cross-linked cyclodextrin: A nanoporous scaffold for enhancement of rosuvastatin oral bioavailability.
Gabr, MM; Mortada, SM; Sallam, MA, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" After LPV loading, the antiviral profile of pHPβCD was reversed to the sigmoidal dose-response profile of LPV, while pMβCD maintained its dose-independent profile followed by a LPV mediated increase in viral inhibition."( Pyromellitic dianhydride crosslinked soluble cyclodextrin polymers: Synthesis, lopinavir release from sub-micron sized particles and anti-HIV-1 activity.
Adeoye, O; Bártolo, I; Cabral-Marques, H; Conceição, J; da Silva, AB; Duarte, N; Francisco, AP; Taveira, N, 2020
)
2
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency68.58960.000714.592883.7951AID1259369
retinoid X nuclear receptor alphaHomo sapiens (human)Potency38.90000.000817.505159.3239AID1159527
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency54.94770.023723.228263.5986AID743222
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency54.42730.000323.4451159.6830AID743066
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency3.44420.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (7.69)18.7374
1990's11 (28.21)18.2507
2000's4 (10.26)29.6817
2010's19 (48.72)24.3611
2020's2 (5.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.25 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index65.65 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies5 (11.90%)4.05%
Observational0 (0.00%)0.25%
Other37 (88.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]